Needham & Company LLC Reiterates Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)
Needham & Company LLC reaffirmed their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a research note released on Tuesday morning,Benzinga reports. Needham & Company LLC currently has a $24.00 price objective on the stock. Several other analysts have also recently weighed in on the stock. D. Boral Capital reiterated a […]
Needham & Company LLC reaffirmed their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a research note released on Tuesday morning,Benzinga reports. Needham & Company LLC currently has a $24.00 price objective on the stock. Several other analysts have also recently weighed in on the stock. D. Boral Capital reiterated a […]